The Justice Department has ended its six-year case accusing Walmart pharmacies of filling invalid opioid prescriptions, and Walmart is paying $50 million — a fraction of the billions the government once said it would seek. The money goes to the federal government, not to customers: there is no claim form and nothing for consumers to file.
Free settlement alerts
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
No. This resolves the federal government's own civil enforcement case against Walmart. The $50 million is a payment to the government, not a class settlement fund, and there is no claim form, no class, and no consumer benefit attached to it.
The government alleged that Walmart pharmacies filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act, and that the company ignored red flags such as dangerous drug combinations, excessive or early refills, and prescriptions written by suspected pill mills. These allegations were never adjudicated. Walmart did not admit liability.
No. Walmart did not admit liability, said it was pleased to resolve the matter, and described the payment as immaterial in a regulatory filing. No court found Walmart liable on the government's claims.
In March 2024 the district judge narrowed the case, dismissing the claims that Walmart failed to report suspicious prescriptions to the DEA and that its pharmacists failed to document red flags. What survived was a narrower claim about prescriptions dispensed when Walmart compliance personnel allegedly knew they were invalid. The parties then filed a joint stipulation dismissing the case.
Walmart entered a memorandum of agreement with the DEA covering its future dispensing of controlled substances. It calls for a hotline that employees and patients can use to report suspected illegal dispensing, proactive monitoring of pharmacy dispensing patterns, and a process for evaluating prescribers suspected of prescribing illegally.
No. This is a federal enforcement case brought by the Justice Department and DEA and is separate from the multistate opioid settlements pharmacy chains and manufacturers reached with state and local governments, and separate from the bankruptcy-driven Purdue Pharma resolution.